Shares of Mineralys Therapeutics, Inc. (MLYS) declined after the company announced a royalty buyout transaction alongside significant new debt and equity financing.
The stock is currently trading at $24.79, down $4.07 or 14.09%, on the Nasdaq. It opened at $26.48 after closing the previous session at $28.85. The stock has traded between $12.59 and $47.65 over the past 52 weeks.
Mineralys agreed to repurchase all future royalty obligations related to lorundrostat from Tanabe Pharma Corporation for $200 million upfront and up to $100 million in future commercial milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.